Fabrication of Nanocrystals for Enhanced Distribution of a Fatty Acid Synthase Inhibitor (Orlistat) as a Promising Method to Relieve Solid Ehrlich Carcinoma-Induced …

JA Alamoudi, TA El-Masry, M Nasr, IT Ibrahim… - Pharmaceuticals, 2024 - mdpi.com
Background: Orlistat (ORL) is an effective irreversible inhibitor of the lipase enzyme, and it
possesses anticancer effects and limited aqueous solubility. This study was designed to …

[HTML][HTML] Therapeutic efficiency of Tamoxifen/Orlistat nanocrystals against solid ehrlich carcinoma via targeting TXNIP/HIF1-α/MMP-9/P27 and BAX/Bcl2/P53 signaling …

TA El-Masry, MMF El-Nagar, GA Oriquat… - Biomedicine & …, 2024 - Elsevier
Abstract Background Orlistat (Orli) is an anti-obesity medication that has been approved by
the US Food and Drug Administration. It has relatively limited oral bioavailability with …

Development of a self-assembled nanoparticle formulation of orlistat, nano-ORL, with increased cytotoxicity against human tumor cell lines

TK Hill, AL Davis, FB Wheeler, SS Kelkar… - Molecular …, 2016 - ACS Publications
Fatty acid synthase (FASN), the enzyme that catalyzes de novo synthesis of fatty acids, is
expressed in many cancer types. Its potential as a therapeutic target is well recognized, but …

Novel orlistat LDL-like nanoparticles as potential anti-cancer medicines

G Bebawy - 2022 - eprints.nottingham.ac.uk
Objectives: The field of Nano-therapeutics has gained vast attention over the past decades,
described as the future cancer medicine. Controlling the particle size is highly crucial for …

Pharmacokinetic and pharmacodynamic evaluation of resveratrol loaded cationic liposomes for targeting hepatocellular carcinoma

S Jagwani, S Jalalpure, D Dhamecha… - ACS Biomaterials …, 2020 - ACS Publications
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related death
worldwide. The destructive nature of the disease makes it difficult for clinicians to manage …

[HTML][HTML] Nano lipidic carriers for codelivery of sorafenib and ganoderic acid for enhanced synergistic antitumor efficacy against hepatocellular carcinoma

B Wang, L Sun, M Wen, Y Tan, WH Almalki… - Saudi Pharmaceutical …, 2021 - Elsevier
The current study focuses on the development and evaluation of nano lipidic carriers (NLCs)
for codelivery of sorafenib (SRF) and ganoderic acid (GA) therapy in order to treat …

Entrapment of an EGFR inhibitor into nanostructured lipid carriers (NLC) improves its antitumor activity against human hepatocarcinoma cells

ML Bondì, A Azzolina, EF Craparo, C Botto… - Journal of …, 2014 - Springer
Background In hepatocellular carcinoma (HCC), different signaling pathways are de-
regulated, and among them, the expression of the epidermal growth factor receptor (EGFR) …

[HTML][HTML] 4-Hexylresorcinol Loaded Solid Lipid Nanoparticles for Enhancing Anticancer Activity

S Yeo, S Jung, H Kim, JH Ahn, SJ Hwang - Pharmaceuticals, 2024 - mdpi.com
Background: Cancer is one of the most significant threats to human health. Following
surgical excision, chemotherapy is an effective strategy against remaining cancer cells. 4 …

Intracellular uptake of etoposide-loaded solid lipid nanoparticles induces an enhancing inhibitory effect on gastric cancer through mitochondria-mediated apoptosis …

J Wang, R Zhu, X Sun, Y Zhu, H Liu… - International journal of …, 2014 - Taylor & Francis
The objective of this study was to prepare and characterize etoposide (VP16)-loaded solid
lipid nanoparticles (SLNs) and evaluate their antitumor activity in vitro. VP16-SLNs were …

The Effect of Nano-Encapsulated Orlistat on Prostate Cancer: An In vitro Study

F Armutcu, B Adam - Journal of Nanotechnology and …, 2024 - scientificarchives.com
Background: The targeted inhibition of fatty acid synthase (FASN) by Orlistat, a potent FASN
inhibitor, has been shown to block tumor proliferation and induce apoptosis in cultured …